Abstracts tagged "rheumatoid arthritis"

Abstract Number: 928 • 2019 ACR/ARP Annual Meeting
Monotherapy with Upadacitinib in MTX-naïve Patients with Rheumatoid Arthritis: Results at 48 Weeks
Ronald van Vollenhoven¹, Tsutomu Takeuchi ², Aileen Pangan ³, Alan Friedman ³, Su Chen ³, Maureen Rischmueller ⁴, Ricardo Blanco ⁵, Ricardo Machado Xavier ⁶ and Vibeke Strand ⁷, ¹Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²Keio University School of Medicine, Tokyo, Japan, ³AbbVie Inc., North Chicago, ⁴Department of Rheumatology, The Queen Elizabeth Hospital and University of Adelaide, South Australia, Australia, ⁵Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, ⁶Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ⁷Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Upadacitinib (UPA), a JAK1-selective inhibitor, was efficacious as monotherapy upto 24 weeks (wks) in MTX-naive patients (pts) with active RA.1 To assess safety and efficacy…
Abstract Number: 1332 • 2019 ACR/ARP Annual Meeting
United States Rheumatology Practice-Based Real-World Evidence of Infusion Reactions in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab or Infliximab: Impact of Prior Biologic Exposure and Methotrexate Utilization
Sergio Schwartzman¹, Aaron Broadwell ², Alan Kivitz ³, Shawn Black ⁴, Stephen Xu ⁵ and Shelly Kafka ⁶, ¹The Hospital for Special Surgery, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY, ²Rheumatology and Osteoporosis Specialists, Shreveport, LA, USA, Shreveport, LA, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, RI, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is an ongoing Phase 4 comparator study designed to provide a…
Abstract Number: 1772 • 2019 ACR/ARP Annual Meeting
Chronotherapy Using Baricitinib Attenuates Collagen-induced Arthritis in Mice
Arisa Yaekura¹, Kanta Morii ², Yuto Oketani ³, Ikumi Okumura ², Kenta Kaneshiro ⁴, Kohsuke Yoshida ², Yoshiko Kawasaki ⁵, Nao Shibanuma ⁵, Yoshitada Sakai ⁶ and Akira Hashiramoto ², ¹Kobe University Graduate School of Health Sciences, Kawanishi, Hyogo, Japan, ²Kobe University Graduate School of Health Sciences, Kobe, Hyogo, Japan, ³Kobe University Graduate School of Health Sciences, Himeji, Hyogo, Japan, ⁴Kobe University Graduate School of Health Sciences, Osaka, Osaka, Japan, ⁵Kobe Kaisei Hospital, Kobe, Hyogo, Japan, ⁶Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
Background/Purpose: Diurnal variations are observed in symptoms of rheumatoid arthritis (RA). Among them, “morning stiffness of joints” is closely reflects the daily medical condition of…
Abstract Number: 2279 • 2019 ACR/ARP Annual Meeting
Pregnancy in Rheumatoid Arthritis: Continue, Reduce or Stop TNF Inhibitors? A Prospective Observational Study
Isabell Haase¹, Susanna Spaethling-Mestekemper ², Ralph Brinks ¹, Matthias Schneider ³ and Rebecca Fischer-Betz ³, ¹Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ²Rheumapraxis, Munich, Germany, ³Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
Background/Purpose: Women with active Rheumatoid Arthritis (RA) are more prone to relapses and complications during pregnancy. The potential risks of disease activation and treatment during…
Abstract Number: 2848 • 2019 ACR/ARP Annual Meeting
Semiquantitative Assessment of Synovial Inflammation on US-Guided Synovial Membrane Biopsy Is Contingent to Disease Phase, Autoimmune Profile and Treatment Response in Rheumatoid Arthritis: Large Single Center Experience (SYNGem Cohort)
Stefano Alivernini¹, Barbara Tolusso ¹, Marco Gessi ², Maria Rita Gigante ¹, Luca Petricca ¹, Clara Di Mario ³, Simone Perniola ¹, Anna Laura Fedele ¹, Giusy Peluso ⁴, Laura Bui ², Annunziata Capacci ¹, Francesco Federico ², Gianfranco Ferraccioli ³ and Elisa Gremese ¹, ¹Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ²Division of Pathology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ³Institute of Rheumatology - Università Cattolica del Sacro Cuore, Rome, Italy, ⁴Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Italy, Italy
Background/Purpose: Ultrasound (US)-guided minimally-invasive Synovial Tissue (ST) biopsy is a well tolerated procedure for basic and translational studies on chronic inflammatory joint diseases as Rheumatoid…
Abstract Number: 44 • 2019 ACR/ARP Annual Meeting
Validation of New Genes Identified in a Molecular Bayesian Network of Rheumatoid Arthritis Synovitis
Teresina Laragione¹, Carolyn Harris ¹, Wenhui Wang ¹, Jun Zhu ¹ and Percio Gulko ¹, ¹Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: We have previously identified new key regulators of Rheumatoid arthritis (RA) synovial pathology using a systems biology approach that combined RA gene expression datasets,…
Abstract Number: 518 • 2019 ACR/ARP Annual Meeting
Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological DMARDs: Results at 60 Weeks
Mark Genovese¹, Bernard Combe ², Stephen Hall ³, Andrea Rubbert-Roth ⁴, Sheng Zhong ⁵, Sebastian Meerwein ⁶, Aileen Pangan ⁷ and Roy Fleischmann ⁸, ¹Stanford University, Stanford, CA, ²CHU Montpellier, Montpellier University, Montpellier, France, ³Monash University and Emeritus Research, Melbourne, Australia, ⁴Kantonsspital St. Gallen, St Gallen, Switzerland, ⁵AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁶AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁷AbbVie Inc., North Chicago, ⁸Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: In patients (pts) with active rheumatoid arthritis (RA) and inadequate response or intolerance to bDMARDs, treatment with upadacitinib (UPA), a JAK1-selective inhibitor resulted in…
Abstract Number: 977 • 2019 ACR/ARP Annual Meeting
Conditional Deletion of MKL1 Inhibits Osteoclast Formation and Bone Erosions in Collagen Induced Arthritis Mice
Wenfeng Tan¹, Aishu Luo ¹, Yong Xu ², Shiyu Lin ³, Miaojia Zhang ⁴ and Fang Wang ³, ¹the First Affiliated Hospital of Nanjing Medical University, Nanjing, China (People's Republic), ²Nanjing Medical University, NANJING, China (People's Republic), ³the First Affiliated Hospital of Nanjing Medical University, Nanjing, ⁴the First Affiliated Hospital of Nanjing Medical University, Najing, China (People's Republic)
Background/Purpose: Excessively osteoclasts (OCs) activation play an essential role in bone erosions in rheumatoid arthritis (RA). Thus, controlling OCs would be an effective strategy to…
Abstract Number: 1340 • 2019 ACR/ARP Annual Meeting
Patterns of Sustained Remission and Subsequent DMARD Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort
Maria Powell¹, Vivian Bykerk ², Orit Schieir ³, Marie-France Valois ⁴, Susan J. Bartlett ⁵, Louis Bessette ⁶, Gilles Boire ⁷, Carol Hitchon ⁸, Edward Keystone ⁹, Janet Pope ¹⁰, Carter Thorne ¹¹, Diane Tin ¹² and Glen Hazlewood ¹, ¹University of Calgary, Calgary, AB, Canada, ²Hospital for Special Surgery, New York City, NY, ³University of Toronto Dalla Lana School of Public Health, Toronto, ON, Canada, ⁴McGill University, Montreal, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Laval University, Quebec City, QC, Canada, ⁷Sherbrooke University, Sherbrooke, QC, Canada, ⁸University of Manitoba, Winnipeg, Canada, ⁹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹⁰Western University, London, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Southlake Regional Health Centre, Newmarket, Canada
Background/Purpose: Rheumatoid arthritis (RA) treatment emphasizes aggressive titration of disease-modifying antirheumatic drugs (DMARDs) with the goal of achieving disease remission. This often includes the use…
Abstract Number: 1774 • 2019 ACR/ARP Annual Meeting
Potential Involvement of OX40 Expressing Tfh Cells on Regulation of Autoantibody Sialylation in Experimental and Rheumatoid Arthritis
Izumi Kurata¹, Isao Matsumoto ¹, Natsuko Mikami ¹, Ayako Ohyama ¹, Atsumu Osada ¹, Yuya Kondo ¹, Hiroto Tsuboi ¹ and Takayuki Sumida ¹, ¹Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Recently, IL-23-Th17 cells axis and hyposialylation of antibodies were proved to be linked to experimental and rheumatoid arthritis. However it remains uncertain how Tfh,…
Abstract Number: 2298 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Disease Is Associated with Distinct Fine Specificities of Anti-Carbamylated Peptide/Protein Antibodies in Rheumatoid Arthritis
Raul Castellanos-Moreira¹, Sebastian Rodriguez-Garcia ², Virginia Ruiz-Esquide ³, Fernanda Hernández-González ⁴, Marcelo Sánchez ⁵, José Ramírez ⁶, Mariana Benegas ⁵, Carmen Lucena-Pozo ⁴, Carlos Agustí ⁴, Marc Boada ⁷, Odette Viñas ⁸, Estíbaliz Ruiz ⁸, Sergio Prieto-González ⁹, Jose Gomez-Puerta ¹, Jacobo Sellares ⁴, Juan Cañete ¹, Isabel Haro ¹⁰ and Raimon Sanmarti ¹, ¹Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ²Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Spain, ³Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ⁴Department of Pneumology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁵Department of Radiodiagnosis, Hospital Clínic, Barcelona, Barcelona, Spain, ⁶Department of Pathological Anatomy, Hospital Clínic, Barcelona, Barcelona, Spain, ⁷Department of Thoracic Surgery, Hospital Clínic, Barcelona, Barcelona, Spain, ⁸Department of Immunology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁹Department of Systemic Autoimmune Diseases Hospital Clínic, Barcelona, Barcelona, Spain, ¹⁰Unit of Synthesis and Biomedical Applications of Peptides, IQAC CSIC, Barcelona, Barcelona, Spain
Background/Purpose: Interstitial lung disease (ILD) is a common and severe complication of rheumatoid arthritis (RA). It has been associated with the presence of ACPA. Anti-carbamylated…
Abstract Number: 2861 • 2019 ACR/ARP Annual Meeting
Lung-Related Factors Are Associated with Transitions from Systemic Anti-CCP Antibody Positivity to Classified RA
Ashley Visser ¹, Marie Feser ², Chelsie Fleischer ³, Laura Lenis-Charry ¹, Justin August ¹, Elizabeth Bemis ⁴, Jill Norris ⁵, V. Michael Holers ⁶, Kevin Deane ² and M. Kristen Demoruelle⁷, ¹University of Colorado Denver, Aurora, ²University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO USA, Aurora, ⁴University of Colorado Denver, School of Public Health, Aurora, CO USA, Aurora, ⁵Colorado School of Public Health, Aurora, ⁶University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁷University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora
Background/Purpose: Systemic autoimmunity associated with RA precedes the onset of inflammatory arthritis (IA) by several years. In particular, the presence of systemic anti-cyclic citrullinated peptide…
Abstract Number: 48 • 2019 ACR/ARP Annual Meeting
Phenotype-based Clustering Along with Analysis of Molecular Profile Might Help to Define Precise CV-risk Profiles in RA Patients
Chary Lopez-Pedrera¹, Nuria Barbarroja ², Maria Luque-Tevar ¹, Patricia Ruiz-Limon ³, Laura Pérez-Sanchez ⁴, Sara Remuzgo-Martínez ⁵, Alejandro Ibañez-Costa ¹, Alejandra Patiño-Trives ¹, Ivan Arias de la Rosa ⁶, Maria del Carmen Abalos-Aguilera ¹, Andres Delgado-Campos ⁷, Rafaela Ortega ¹, Raquel López-Mejías ⁵, M Angeles Aguirre ⁸, Alejandro Escudero ⁷, Eduardo Collantes-Estevez ⁶, Miguel A. González-Gay ⁹ and Carlos Perez-Sanchez ¹⁰, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, ³Research Group of Endocrine Diseases, Research Laboratory. Biomedical Research Institute of Malaga (IBIMA).Virgen de la Victoria Universitary Hospital, Malaga, Spain, Málaga, Spain, ⁴MIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁵Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ⁶University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁷IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁸IMIBIC/Reina Sofia Hospital/University of Cordoba,, Córdoba, Spain, ⁹Hospital Universitario Marqués de Valdecilla. IDIVAL. Universidad de Cantabria., Cantabria, Spain, ¹⁰Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain
Background/Purpose: 1. To identify and characterize specific immunological, inflammatory and epigenetic determinants involved in the enhanced cardiovascular (CV)-risk present in Rheumatoid Arthritis (RA) patients. 2.…
Abstract Number: 521 • 2019 ACR/ARP Annual Meeting
Discontinuation of Disease Modifying Drugs Due to Inefficacy in Patients with Incident Rheumatoid Arthritis
Zulema Rosales Rosado¹, pia Lois ¹, Arkaitz Mucientes Ruiz ¹, Esperanza Pato Cour ¹, Dalifer Freites Nuñez ², Juan Angel Jover Jover ¹, lydia Abasolo Alcazar ¹ and Leticia León ³, ¹HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ²Hospital Clínico San Carlos, MADRID, Spain, ³Fundación para la Investigación Biomedica, Madrid, Madrid, Spain
Background/Purpose: The treatment of Rheumatoid Arthritis (RA) has undergone a big change in the last two decades with the Disease Modifying Drugs (DMARDs). These drugs…
Abstract Number: 978 • 2019 ACR/ARP Annual Meeting
Light Mediated Therapeutics in Arthritis
Victoria Wickenheisser¹, Emily Rabjohns ², Emilia Zywot ³, Natalia Orlova ³, Christina Marvin ³, Song Ding ⁴, David Lawrence ⁴ and Teresa Tarrant ⁵, ¹Duke University School of Medicine, Durham, ²Department of Rheumatology, Duke University Hospital, Durham, NC, ³UNC Department of Chemistry, Chapel Hill, NC, ⁴Division of Medicinal Chemistry and Chemical Biology The UNC Eshelman School of Pharmacy at UNC, Chapel Hill, NC, ⁵Department of Medicine Division of Rheumatology and Immunology, Duke University Hospital, Durham, NC
Background/Purpose: Rheumatoid arthritis (RA) therapies are constrained by the failure to deliver sufficient quantities of drug to the inflamed site, systemic side effects, and the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].